secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001171843-22-007012
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics raises $80M in PIPE led by Enavate; extends cash runway to 2026
--------------------------------------------------------------------------------

- Issues 25M shares at $3.21 each for gross proceeds of ~$80M; closing expected by Nov 8, 2022.
- PIPE led by Enavate Sciences with participation from Janus Henderson, Vivo Capital, OrbiMed, and others.
- New director James P. Boylan (CEO of Enavate) appointed to board, effective upon closing.
- Proceeds to fund CTX-009, CTX-471, CTX-8371 clinical programs and preclinical work; cash runway extended into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/0001171843-22-007012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184322007012/f8k_110222.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer